B细胞成熟抗原在多发性骨髓瘤免疫治疗和分子影像中的应用进展  

Advances in immunotherapy and molecular imaging of B-cell maturation antigen in multiple myeloma

作　　者：宋乐乐 杨奕涵 康磊[1] SONG Lele;YANG Yihan;KANG Lei(Department of Nuclear Medicine,Peking University First Hospital,Beijing 100034,China)

机构地区：[1]北京大学第一医院核医学科,北京100034

出　　处：《现代肿瘤医学》2024年第23期4517-4521,共5页Journal of Modern Oncology

基　　金：国家自然科学基金面上项目(编号:82171970);北京市杰出青年科学基金项目(编号:JQ21025);北京市科学技术委员会首都临床特色应用研究项目(编号:Z221100007422027)。

摘　　要：多发性骨髓瘤(multiple myeloma,MM)是一类源自血液系统的恶性肿瘤,其主要特点是骨髓中克隆性浆细胞的异常增长,这些细胞会分泌单克隆免疫球蛋白,进而损害靶器官。B细胞成熟抗原(B cell maturation antigen,BCMA)在恶性浆细胞中显著表达,而在正常细胞(仅限于浆细胞、部分成熟B细胞及CD34+干细胞)中则无表达,因此被视为MM诊断和治疗的理想靶点。该文综述了近年来BCMA在MM中的分子机制、靶向免疫治疗以及BCMA靶向分子影像探针的研究进展。Multiple myeloma(MM)is a hematologic malignancy characterized by the abnormal proliferation of clonal plasma cells in the bone marrow,which secrete monoclonal immunoglobulins that subsequently damage target organs.The B cell maturation antigen(BCMA)is highly expressed in malignant plasma cells but is absent in most normal cells,being limited to plasma cells,some mature B cells,and CD34+stem cells.Consequently,BCMA is considered an ideal target for both the diagnosis and treatment of MM.This paper reviews the molecular mechanisms of BCMA in MM,along with the advancements in targeted immunotherapy and BCMA-targeted molecular imaging probes.

关 键 词：多发性骨髓瘤 B细胞成熟抗原 正电子发射断层显像术 免疫治疗 

分 类 号：R733.3[医药卫生—肿瘤]